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 Wilms tumor (WT) is a childhood tumor of the kidney and a productive model for 
understanding the role of genetic alteration and interactions in tumorigenesis. The Wilms 
tumor gene 1 (WT1) is a transcriptional factor and one of the few genes known to have 
genetic alterations in WT and has been shown be inactivated in 20% of WTs. However, the 
mechanisms of how WT1 mutations lead to Wilms tumorigenesis and its influence on 
downstream genes are unknown. Since it has been established that WT1 is a 
transcriptional regulator, it has been hypothesized that the loss of WT1 leads to the 
dysregulation of downstream genes, in turn result in the formation of WTs. To identify the 
dysregulated downstream genes following WT1 mutations, an Affymetrix GeneChip 
Human Genome Array was previously conducted to assess the differentially expressed 
genes in the WT1-wildtype human and WT1-mutant human WTs. Approximately 700 
genes were identified as being significantly dysregulated. These genes were further 
prioritized based on their statistical significance, fold change, chromosomal region, spatial 
pattern of gene expression and known or putative cellular functions. Mesenchyme 
homeobox 2 (MEOX2) was one of the most significantly upregulated genes in WT1-mutant 
WT. MEOX2 is known to play a role in cell proliferation, apoptosis, and differentiation. In 
addition to its biological roles, it is expressed during early kidney development in the 
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condensed mesenchyme similar to WT1. Furthermore, the use of the Match® web-based 
tool from the BIOBASE Biological Data base identified a significant predicted WT1 binding 
site within the first intron of MEOX2. The similarity in spatial gene expression in the 
developing kidney and the significant predicted WT1 binding site found in the first intron of 
MEOX2 lead to the development of my hypothesis that MEOX2 is upregulated via a WT1-
dependent manner.  
Here as a part of my master’s work, I have validated the Affymetrix GeneChip 
Human Genome Array data using an independent set of Wilms tumors. MEOX2 remained 
upregulated in the mutant WT1 Wilms tumor by 41-fold. Wt1 and Meox2 gene expression 
were assessed in murine newborn kidney; both Wt1 and Meox2 were expressed in the 
condensed, undifferentiated metanephric mesenchyme. I have shown that the in vivo 
ablation of Wt1 during embryonic development at embryonic day (E) 13.5 resulted in the 
slight increase of Meox2 gene expression by two fold. In order to functionally demonstrate 
the effect of the loss of Wt1 on Meox2 gene expression in undifferentiated metanephric 
mesenchyme, I have generated a kidney mesenchymal cell line to genetically ablate Wt1 
in vitro by adenoviral infection. The ablation of Wt1 in the kidney mesenchymal cell line 
resulted in the upregulation of Meox2 by 61-fold. Moreover, the upregulation of Meox2 
resulted in the significant induction of p21 and Itgb5. In addition to the dysregulation of 
these genes the ablation of Wt1 in the kidney mesenchymal cells resulted in decrease in 
cell growth and loss of cellular adherence. However, it is uncertain whether the 
upregulation of Meox2 caused this particular cellular phenotype. Overall, I have 
demonstrated that the upregulation of Meox2 is Wt1-dependent during early kidney 
development.  
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Chapter 1: Introduction 
Wilms Tumor 
Wilms tumor (WT) is an embryonal malignancy of the kidney that represents 
approximately 95% of all pediatric kidney tumors and accounts for 6% of all pediatric 
cancers (1-4). The overall annual incidence of Wilms tumor in North America is 1 in 
10,000 children, resulting in 600-700 new cases each year (3, 4). Approximately 75% 
of these WTs occur in children under the age of 5 years, with a peak occurrence 
between 3-4 years of age (5). WTs can be classified into three clinical categories 
based on its occurrence: 1) the sporadic category, which describes children with no 
unusual physical features or family history of WT; 2) the familial category, which 
describes children with family history of WT; and 3) the syndromic category, which 
describes children with congenital anomalies, such as Wilms tumor, aniridia, 
genitourinary malformation, and mental retardation (WAGR) syndrome, Denys-Drash 
syndrome (DDS), and Beckwith–Wiedemann syndrome (BWS). Between 98-99% WT 
cases are sporadic, while only 1-2% are familial (1, 3, 6). The majority of WT cases 
(90-95%) are unilateral (occurring in one kidney). However, bilateral cases (occurring 
in both kidneys) are also reported, particularly in patients with congenital anomalies as 
well as a family history of WTs (1, 7). Because WT is thought to occur during early 
kidney development, it serves as an excellent model to study the relationship of cancer 
to development by understanding normal kidney development and how a disruption 
during this process results in Wilms tumorigenesis.  
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Kidney Development  
The mammalian kidney arises during embryogenesis from the interaction 
between the differentiated epithelial cells of the ureteric bud and undifferentiated 
mesenchymal cells (8, 9). In mice, the ureteric bud epithelium invades the 
uncondensed, undifferentiated metanephric mesenchyme, which causes the 
metanephric mesenchymal cells to condense around the ureteric bud (Figure 1.1 A-
C). Reciprocal interactions occur between the ureteric bud and the metanephric 
mesenchyme. The ureteric bud induces the metanephric mesenchyme to 
simultaneously give rise to stromal mesenchyme, which is rich in growth factors and 
corresponding receptors for the adjacent epithelial ureteric bud. Concurrently, the 
metanephric mesenchyme further condenses around the ureteric bud to undergo a 
mesenchymal-to-epithelial transition (MET) (8-11). Simultaneously, the induced 
mesenchyme forms into the comma and S-shaped bodies as the ureteric bud 
continues to branch out and proliferate (Figure 1.1 D-E) (8-10). The S- and comma- 
shaped bodies of the mesenchyme completely differentiates into epithelial cells to 
make up the majority of the cells of the nephron, such as the tubules and glomeruli 
(Figure 1.1 F-G) (8-10). The extensive branching of the ureteric bud results in the 
generation of the collecting ducts of the mature kidney, and the kidney continues to 
develop into the mature kidney after birth in mice (8-10). The stages of kidney 
development in humans occur similar to that in mice.  
 WT is thought to arise from undifferentiated metanephric mesenchyme. The 
classic histology of WTs, in both humans and mice, is triphasic consisting of 
mesenchymal, stromal, and epithelial cells that suggest disruption(s) during the 
cellular differentiation in the cells of the maturing nephron (Figure 1.2). Some 
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individual WTs consist of two of the three cell types; one cell type can be predominant 
over the other cell types present in the tumor.  Because of the classic triphasic 
histology of WT, it is thought that there was a disruption during early kidney 
development, particularly in the cellular differentiation. This disruption may inhibit the 
cells to differentiate into the components of the nephron and cause them to 
overproliferate, in turn resulting in WT.  
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Figure 1.1. Kidney Development  
Kidney development in mice starts at embryonic day (E) E10.5-11.5. In the beginning, the uncondensed mesenchyme 
(A) is invaded by the ureteric bud (B). At E12.5, the mesenchyme becomes condensed (C). At E13.5, comma-shaped bodies 
and S-shaped bodies (D and E) start to appear during kidney development. At E14.5, the tubular component of the nephron 
continues to develop into the functionally distinct cells of the proximal convoluted tubule, descending and ascending tubule (F) 
and the mesenchymal cells transition to become epithelized and differentiate into specialized cells of the glomerulus and 
tubules of the mature nephron (G) In humans, kidney development occurs similar to that in mice (10, 12). (Adapted from (12))
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Figure 1.2. Hematoxylin and Eosin Staining of Newborn Mouse Kidney and WTs 
The triphasic histology of WTs in both human and mouse illustrates the early stages of kidney development (B- 
Blastemal, S- Stromal, and E- Epithelial cells).  (Provided by Gao, F. and Hu, Q.) 
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Genetic Alterations in Wilms Tumor 
WT was the second tumor to meet the criteria of the Knudson’s two hit model of 
cancer, in which there are two rate-limiting events, or ‘hits’, in turn resulting in cancer 
formation (13). The two rate-limiting events are a first ‘hit’, (which can be either a 
germline or somatic mutation), which may be followed by a second ‘hit’, always a 
somatic mutation (13). Besides the two rate-limiting events of the classic Knudson’s 
two hit model, it has been suggested that there could be multiple genetic alterations 
and/or multiple mutated genes involved in an individual WT. Cytogenetic, genetic 
linkage, loss of heterozygosity (LOH), loss of imprinting (LOI), and DNA sequencing 
studies provided data that identified alterations that occur during Wilms tumorigenesis.  
Cytogenetic studies, such as G-Banding, fluorescent in situ hybridization (FISH) 
and comparative genomic hybridization (CGH), revealed chromosomal alterations, 
including the gain and loss of chromosomes and chromosomal regions in WTs. The 
chromosomal gains in WTs were observed in  chromosomes 6, 7, 12, 13, 17, 18, and 
20 and the chromosomal losses noted in chromosomal regions  1p, 2q, 3, 7p, 11p, 
11q, 14q, 16q, 17p, and 22q (14-17). These chromosomal regions may harbor genes 
that contribute to Wilms tumorigenesis. 
As of now, genetic linkage studies mapped chromosomal region 17q12-q21 as 
familial Wilms Tumor gene 1 (FWT1) and chromosomal region 19q13.4 as familial 
Wilms tumor gene 2 (FWT2) as familial predisposition regions in large WT families. 
These regions may contain genes that predispose to WT (18, 19). However, no genes 
have yet been identified within these regions that contribute to the familial 
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predisposition of WT. The mapping of additional chromosomal regions in WT families 
is still an ongoing process.  
Additional to cytogenetic analyses, LOH studies identified the loss of 
chromosomal region 11p in tumors versus constitutional DNA from the same 
individual. The demonstration of LOH at loci 11p in ~40% of WTs suggested that the 
inactivation of the gene within this particular region is essential to Wilms tumorigenesis 
(20-22). In addition to the LOH of 11p chromosomal region, WAGR patients carried 
constitutional deletions encompassing band 11p13 (17). Kaneko et al. reported that 
subsequent observation of 11p13 deletions in tumor DNA from patients who did not 
carry germline 11p13 deletions indicated somatic mutations were also essential during 
tumorigenesis (23). Collectively, these analyses of 11p13 deletions led investigators to 
localize and clone the first WT gene, Wilms tumor gene 1 (WT1) (24). This particular 
gene is mutated in ~20% of WTs (1).  
DNA sequencing analysis data identified additional genetic alterations in 
identifiable genes in WTs.  The tumor suppressor protein p53 (TP53), located at 
chromosome region 17p13, is mutated in 5% of WTs (25, 26). The tumors that carry 
p53 mutations contain abnormal cells that are poorly developed with enlarged 
distorted nuclei (25, 26). Germline and somatic mutations of TP53 include either 
missense mutations that occur in the exons 5, 6, and 10, and lead to the inactivation of 
the protein (25). Catenin (cadherin-associated protein), beta 1 (CTNNB1), located at 
chromosomal region 3p21, is mutated in 15% of sporadic WTs (27, 28). Somatic 
mutations of CTNNB1 include protein-stabilizing mutations in exon 3 (27, 28). 
Additional mutations occur in exons 7 and 8 of CTNNB1 (29, 30). Recently, Wilms 
tumor gene located at Xq11.1 (WTX) was discovered to be mutated in ~20% of WTs 
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(31-34). Somatic mutations of WTX include either whole or partial deletion of WTX or 
nonsense mutations resulting in termination codons (31-34). The discovery of all the 
genetic alterations and identifiable mutated genes involved during Wilms 
tumorigenesis is still in progress. WT1 is one of the genes that is commonly mutated in 
WTs and essential during kidney development as later described. It is important to 
further study the loss of WT1 in order to determine and establish its fundamental role 
during Wilms tumorigenesis. 
 
Wilms Tumor Suppressor Gene 1 (WT1) 
 Located at 11p13 in humans, the WT1 gene consists of ten exons and encodes 
a zinc finger transcriptional factor which contains a proline glutamine-rich protein-
interaction domain and four carboxy-terminal zinc finger domains (24, 35) (Figure 
1.3A). Four isoforms of the WT1 protein result from two different alternative splice 
sites.  Alternative splice I inserts the entire exon 5, which is made up of 51 nucleotides 
and  encodes 17 amino acids (Figure 1.3B) (36). Alternative splice II inserts 9 
nucleotides in exon 9 that encodes an additional three amino acids, lysine [K], 
threonine [T], and serine [S] (Figure 1.3B) (36).  
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Figure 1.3. WT1 Gene and Protein  
 1.3A. Exons are indicated by yellow and the alternative splice sites are located 
within exons 5 and 9 that result in four different isoforms of the WT1 protein (36).  
 1.3B. Proline and glutamine rich domain (blue) and four zinc fingers that serve 
as the DNA binding domain (green) of the WT1 protein (36). (Adapted from (7)) 
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Wt1 in Kidney Development 
 At E9.5 in mice, the first expression of Wt1 is in the intermediate mesenchyme 
lateral to the coelomic cavity (37). Wt1 is later expressed in the metanephric 
mesenchyme (uncondensed and condensed) (Figure 1.4) and its maximum 
expression is in the S- and comma-shaped bodies (9, 38-42). In the adult kidney, it is 
restricted to the podocytes of the glomerulus (Figure 1.4) (10, 42). The essential role 
of Wt1 during kidney development was not recognized until a mouse model was 
generated for the purpose of investigating the role of Wt1 in development, 
homeostasis, and WT development.  
Kreidberg et. al. (1993) first generated a Wt1 mouse model (43). Heterozygous 
mutant Wt1 mice appeared to be normal; however homozygous mutant Wt1 mice were 
typically embryonic lethal between E13 and E15 (43). Homozygous mutant Wt1 mice 
failed to complete gestation due to systemic edema and pericardial bleeding (43). 
Besides embryonic lethality, the major consequence of Wt1 mutation was renal 
agenesis (43). Hu et. al. (2011) also demonstrated that the in vivo ablation of Wt1 in a 
conditional inducible knock out mouse model resulted in a complete block in nephron 
development, in which no glomeruli were present, and there was no differentiation of 
condensed mesenchyme past the comma-shaped body stage (44). All together, Wt1 
has an essential role, direct or indirect, in the survival and differentiation of the 
metanephric mesenchymal cells during kidney development.  
11 
 
 
 
 
 
 
 
 
Figure 1.4. Wt1 Protein Expression during Murine Kidney Development 
 Wt1 is expressed in the uncondensed and condensed mesenchyme (left) and expression remains high 
throughout kidney development, especially in the S- and comma-shaped bodies (middle). Its expression is restricted to 
the podocytes of the glomerulus (right) (45). (Provided by Gao, F. and Hu, Q.). 
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WT1 in Wilms Tumor 
 Germline and sporadic mutations of WT1 in WTs consist of alterations such as 
deletions or insertions leading to frameshift and/or truncation, missense and nonsense 
mutation, or splice site mutations that result in the inactivation of the WT1 protein 
(Figure 1.5) (1, 32, 46). These mutations lead to the inactivation of the protein (1, 32). 
WT1 germline mutations occur in children with congenital anomaly syndromes, such 
as WAGR and DDS, and have a high risk of developing WTs (1, 32). In regards to 
WT1 mutations in sporadic WTs, numerous of studies have gathered data providing 
different frequencies of WT1 mutations ranging from 10-20% (47-50). Furthermore, 
patients with homozygous mutations within WT1 provided evidence that mutations in 
both alleles at the WT1 locus are critical in WT development and define the functional 
role of WT1 in WT as a tumor suppressor gene (1, 47). Even though genetic studies 
identified germline and somatic mutations that result in the inactivation of WT1 in WTs, 
the effect of the loss of WT1 during Wilms tumorigenesis remains unknown. Since 
WT1 is a transcriptional factor that regulates the activation or repression of genes, the 
driving hypothesis is that the inactivation of WT1 results in the dysregulation of 
downstream genes that are involved in key cellular pathways during embryogenesis 
that contribute to Wilms tumorigenesis.   
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Figure 1.5. WT1 mutations detected in WTs 
 Germline mutations, dispersed throughout the entire WT1 gene, detected in 
patients with Wilms’ tumor-associated phenotypes. Similar mutations were detected in 
somatically mutated WTs.  Location of gene mutations are designated by red (insertion 
or deletions and frameshift mutations), blue (nonsense mutations), and green (splice 
site mutations). (Adapted from (51)).  
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Genes Regulated by WT1 
Genes regulated by WT1 have been identified and are involved in pathways 
that are essential in cellular proliferation, apoptosis, cell survival, and cellular 
differentiation. The identification of the majority of genes regulated by WT1 was done 
by promoter assays, electrophoretic mobility shift assay (EMSA), co-
immunoprecipitation (co-IP), microarray analyses, and co-transfection assays (52-
124). These in vitro assays were conducted with human cell lines derived from normal 
and cancerous tissues and/or murine cell lines (52-124). A collection of published 
genes thought to be regulated by WT1 is displayed in Appendix Table 1. However, it 
is unclear whether the inactivation of WT1 has an influence on their gene expression 
during Wilms tumorigenesis. To determine the effect of the loss of WT1 on the 
downstream genes, a previous Affymetrix GeneChip Human Genome Array was used 
as an approach to identify genes that are differentially expressed in human WT1-
mutant WTs when compared to WT1-wildtype WTs. Approximately 700 genes were 
significantly differently expressed from this array (Ruteshouser, E. C.).  These genes 
were prioritized by their False Discovery Rate (FDR, 0.05), statistical significance (p-
Value <0.05), fold change (>2X), chromosomal region, and gene expression pattern. 
Moreover, extensive literature searches on their known or putative cellular functions 
narrowed the number of genes for further investigation to 223 genes. The effect of the 
loss of WT1 resulted in the differentially expression of a variety of genes; however, it 
remains unknown whether the effect of the inactivation of WT1 dysregulates their gene 
expression during early kidney development, which could lead to the development of 
WTs.   
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Rationale 
WT1 is known to be both an essential gene during kidney development and a 
tumor suppressor of WT. WT1 is reported mutated in WTs, however the effect of the 
loss of WT1 during Wilms tumorigenesis remains uncertain. Potentially, WT1 
transcriptionally regulates genes involved in signaling pathways that control cellular 
processes, such as cellular proliferation, differentiation, apoptosis, and cell adhesion. 
The hypothesis of the inactivation of WT1 in WT is that it results in the transcriptional 
dysregulation of downstream genes that lead to Wilms tumorigenesis. To test the 
hypothesis, a microarray was conducted and identified numerous genes that were 
either upregulated or downregulated in WT1-mutant WTs. The microarray data support 
the hypothesis that the inactivation of WT1 transcriptionally dysregulates downstream 
genes. I have propose to investigate the loss of Wt1 during murine kidney 
development to determine whether the gene is expressed during early kidney 
development, whether Wt1 regulates, directly or indirectly, the gene during kidney 
development, and whether their dysregulation in gene expression following a Wt1 
mutation lead to the formation of WT. 
I have taken the first step to determine the effect of inactivation of WT1 on the 
genes dysregulated in WTs by validating the microarray data by quantitative PCR 
(qPCR) using an independent set of WTs to rule out any false discoveries from the 
microarray data (Chapter 2). The qPCR validation revealed a stronger gene regulation 
relationship between WT1 and MEOX2. Therefore, the goal of my project is to further 
assess the effect MEOX2 gene expression following a WT1 mutation during kidney 
development.   
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Because it is thought that a disruption in the cellular differentiation process 
during early kidney development leads to Wilms tumorigenesis, I generated a number 
of conditional Wt1 immortalized undifferentiated metanephric mesenchymal cell lines 
(MMCs) (Chapter 3). I used this cell line to determine the expression level of Meox2 
before and after the ablation of Wt1. To assess the dysregulation of Meox2 following a 
Wt1 mutation during early kidney development in vivo, I used the Wt1 conditional 
knockout mouse model to ablate Wt1 at E11.5 and determined the dysregulation of 
Meox2 at E13.5 (Chapter 4). Results from both the in vivo and in vivo studies indicated 
that the inactivation of Wt1 results in the upregulation of Meox2 during early kidney 
development. Furthermore, the upregulation of Meox2 from the in vitro analyses 
showed an effect on Meox2 established downstream genes, p21 and Itgb5. My studies 
of the effect of gene expression of Meox2 following a Wt1 mutation suggest that Wt1 
regulates Meox2 during both early kidney development and Wilms tumorigenesis.  
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Chapter 2: Upregulation of MEOX2 in WT1-mutant tumors: Validation of WT1 
Putative Transcriptional Targets by qPCR 
 WT1 is expressed during early kidney development and encodes a 
transcriptional factor and tumor suppressor that recognizes several DNA motifs such 
as the early growth response-1 (EGR-1) binding site, TCC repeats, and a high affinity 
WTE site (55, 71, 101, 125, 126). As displayed in Appendix Table 1, WT1 putatively 
activates or represses its downstream genes. Thus, the effect of the loss of WT1 
during Wilms tumorigenesis could be the increased or decreased expression of 
downstream genes during early kidney development. Our recent microarray data 
identified genes that were dysregulated due to the inactivation of WT1 in WTs. Some 
of these dysregulated genes are known to be normally expressed in the kidney, while 
others were not.  
 Our previous Affymetrix GeneChip array data revealed numerous genes that 
were significantly dysregulated in WT1-mutant WTs. As previously mentioned in 
Chapter 1, stringent statistical analysis of the microarray data and literature searches 
further narrowed down the number of genes to 21 as the most significant dysregulated 
genes in WT1-mutant WTs. Seven out of the 21 genes were selected, based on their 
biological relevance(s) in kidney development and cancer, for further investigation 
(Table 2.1). Two of these genes, Discoidin domain receptor family, member 1 (DDR1) 
and Homeodomain-interacting protein kinase 2 (HIPK2), are involved in cellular 
proliferation and/or apoptosis (Table 2.2) (127). Three of these genes, CXXC-type zinc 
finger protein 4 (CXXC4), Follistatin (FST), and HIPK2, play roles in signaling 
pathways which promote cellular proliferation and differentiation (Table 2.2) (127). 
Another gene, Myeloid/lymphoid or mixed-lineage leukemia, translocated to 3 
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(MLLT3), is involved in transcriptional regulation (Table 2.2) (127). Additionally, two 
genes, Mesenchyme Homeobox gene 2 (MEOX2), and Paired related homeobox 1 
(PRRX1), are located in chromosomes 1 and 7, which have been identified in WTs 
with genetic aberrations. The dysregulation of these genes following mutation WT1 
suggests that WT1 potentially regulates them during kidney development. Like WT1, 
these genes are expressed during embryogenesis, which also supports the hypothesis 
that WT1 transcriptionally regulates these genes. Before we can further study the 
effect of inactivation of WT1 on the gene expression of CXXC4, DDR1, FST, HIPK2, 
MEOX2, MLLT3, and PRRX1, the problem of false discovery from the array data has 
to be resolved. 
 A method to assess any false discoveries from the microarray is by quantitative 
PCR (qPCR) that quantifies the relative or absolute gene expression level within a 
given sample. In order to further investigate the effect of inactivation of WT1 on the 
gene expression of CXXC4, DDR1, FST, HIPK2, MEOX2, MLLT3, and PRRX1, I 
validated all these genes with RNA isolated from an independent set of WTs by qPCR. 
Here, it is reported that the gene expression of MEOX2, one of the seven selected 
genes, stood out from the other validated genes and was significantly upregulated in 
WT1-mutant tumors. This suggested that WT1 transcriptionally, directly or indirectly, 
regulates MEOX2 during early kidney development and Wilms tumorigenesis.  
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Table 2.1. Selected Differentially Expressed Genes from the Affymetrix GeneChip Array   
 
 
 
 
 
Gene ID Protein Location Fold Change  
CXXC4 CXXC-type zinc finger protein 4 4q22-q24 2.5-5X ↓ 
DDR1 Discoidin domain receptor family, member 1 6p21.3 2.5-3X ↓ 
FST Follistatin 5q11.2 6-17X ↑ 
HIPK2 Homeodomain-interacting protein kinase 2 7q32-q34 2-5X ↓ 
MEOX2 Mesenchyme Homeobox gene 2 7p22-p21 19X ↑ 
MLLT3 
Myeloid/lymphoid or mixed-lineage leukemia, 
translocated to 3 9p22 5-7X ↑ 
PRRX1 Paired related homeobox 1 1q24 4-7X ↑ 
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Gene ID Function* Process* Component*
Cxxc4 DNA binding Wnt Signaling Pathway Cytoplasm
PDZ domain binding Cytoplasmic membrane
Metal ion binding Cytoplasmic vesicle
Zinc ion binding
Ddr1 ATP binding Cell adhesion Basolateral plasma membrane 
Kinase activity Ear development Integral to membrane
Nucleotide binding Embryo implantation Integral to plasma membrane
Protein binding Cell proliferation Membrane
Protein kinase activity Mammary gland alveolus development Plasma membrane
Protein tyrosine kinase activity Peptidyl-tyrosone phosphorylation
Receptor activity Protein phosphorylation
Transferase activity Transmembrane receptor protein tyrosine kinase signaling pathway
Transmembrane receptor protein tyrosine kinase activity
Fst Activin binding BMP Signaling Pathway Extracellular region
Heparan sulfate proteoglycan binding Female gonadal development
Gamete development
Hair follicle development
Hemopoietic progentitor cell differentiation
Keratinocyte proliferation
Cell differentiation
Pattern specification process
Hipk2 ATP binding DNA damage response PML body
SMAD binding SMAD protein signal transduction Centrosome
Nucleotide binding Anterior/posterior pattern formation Cytoplasm
Protein binding Apoptosis Nulear body
Protein kinase activity BMP Signaling Pathway Nuclear membrane
Transcritpion corepressor activity Phosphorylation Nucleus
Transferase activity DNA binding
Virion binding JNK cascade
Cell Proliferation
Smoothen signaling pathway
TGF-beta receptor signaling pathway
Meox2 DNA binding Angiogenesis Cytoplasm
Sequence-specific DNA binding Limb development Nucleus
Sequence-specific DNA binding transcription factor activity Multicellular organismal development
Transcription regulator activity Palate development
Regulation of transcription, DNA-dependent
Skeletal muscle tissue development
Somite specification
Table 2.2. Biological and Cellular Description of the Selected Genes  
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Information provided by: 
Mouse Genome Informatics (MGI)*  
 
 
 
Gene ID Function* Process* Component*
Mllt3 Protein binding Anterior/posterior pattern formation Nucleus
Regulation of transcription, DNA-dependent Cytoplasm
Segment specification
Prrx1 DNA binding Artery morphogenesis Nucleus
Sequence-specific DNA binding Cartilage development
Sequence-specific DNA binding transcription factor activity Embryonic cranial skeleton morphogenesis
Transcription regulator activity Embryonic skeletal system morphogenesis
Transcription repressor activity Inner ear morphogenesis
Middle ear morphogenesis
Multicellular organismal development
Palate development
Regulation of transcription, DNA-dependent
22 
 
Materials and Methods 
Wilms Tumor Samples 
 Twelve WT samples were used to validate the microarray data. Previously, WT 
samples, after informed consent, were collected from sporadic WT patients (50, 128). 
The DNA extracted from the tumors were analyzed for mutations by PCR amplification 
by the use of primers flanking each of the 10 exons of WT1, and followed by single-
strand conformation polymorphism (SSCP) to confirm the abnormality (50, 129). The 
identification of WT1 mutations was by the direct sequencing of aberrant PCR 
products (50)..  
 
Isolation of RNA from Human Wilms Tumor Samples 
 The isolation of RNA was previously achieved by either acid guanidinium 
thiocyanate-phenol-chloroform extraction, described by Chomczynski, P. and N. 
Sacchi (130), RNAqueous®-4PCR Kit from Applied Biosystems (Carlsbad, California), 
or RNeasy Midi Kit from Qiagen (Valencia, CA). Depending on the method used to 
isolate the RNA, it was kept in solution in either diethyl pyrocarbonate (DEPC) treated 
water or in ethanol. Samples were stored at -80°C.   
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Quantitative PCR  
 qPCR is an efficient quantitative approach to validate the dysregulated genes 
from the microarray data. cDNAs were prepared by reverse transcription of 500 ng of 
total RNA from human WT1-wildtype and WT1-mutant Wilms tumors using TaqMan 
Reverse Transcription reagents with random hexamers from Applied Biosystems 
(Carlsbad, California). cDNAs were then amplified in duplicate in an ABI 7900HT 
Sequence Detection System thermal cycler using SYBR Green PCR Master Mix 
(Applied Biosystems). Primer Express v.3 software (Applied Biosystems) was used to 
design primer sets for the individual genes (Table 2.3). To determine the specificity of 
these primer sets, a dissociation curve of each primer set was assessed using human 
fetal kidney by qPCR analysis. Expression of glyceraldehyde phosphate 
dehydrogenase (GAPDH) was determined as an endogenous gene expression 
control. The standard deviation (SD) was determined for duplicate measurements of 
gene expression. 
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Table 2.3. Primer Sets designed by Primer Express v.3 Software for the qPCR 
Validation 
Name Sequence (5'-3') 
CXXC4 F AAAACCTGGCACTTCACTAGAGAGA 
CXXC4 R CTTTAAAAGAACCATCGGAATGCT 
DDR1 F CCCACCATCAGCTACCCAAT 
DDR1 R AAGTCTGCGATTTTGATGGTGAA 
FST F TGCTGGGCAGATCTATTGGAT 
FST R GATATCTTCACAGGACTTTGCTTTGA 
HIPK2 F CACCATGACACACTTACTCGATTTT 
HIPK2 R CACCCGACGCTTGCAGAT 
MEOX2 F CTGCGGAGGCGGAGAA 
MEOX2 R CTTGTAATTTCCTTCCTGGGAGTCT 
MLLT3 F GCAGCAGATCGTGAACCTTATAGA 
MLLT3 R CGAGCAAAGATCAAATCAAATGT 
PRRX1 F CAGCGTCTCCGTACAGATCCT 
PRRX1 R CGTTATGAAGCCCCTCGTGTAA 
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Results  
Validation of the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array 
 CXXC4, DDR1, FST, HIPK2, MEOX2, MLLT3, and PRRX1 were validated by 
qPCR with a total of 12 WTs samples, six WT1-wildtype WTs and six WT1-mutant 
WTs. CXXC4, DDR1, and HIPK2 were downregulated and FST, MEOX2, MLLT3, and 
PRRX1 were upregulated in WT1-mutant WTs by qPCR analysis (Figure 2.1 and 
Table 2.4). The upregulation of MEOX2 stood out far from the rest of the dysregulated 
genes in the WT1-mutant WTs, therefore suggesting that WT1 would normally 
transcriptionally repress the gene expression of MEOX2, but the loss of WT1 results in 
the overexpression of MEOX2.  
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Figure 2.1. Validation of the Dysregulated Genes in the WT1-mutant WTs 
 In this graph, the y-axis represents the gene expression detected by the specific 
designed primer sets relative to the gene expression in the WT1-wildtype WTs. The 
individual color of the bars represents the gene found upregulated or downregulated in 
the WT1-mutant WTs.  
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Discussion  
 It is important to identify genes that play a role in regulating cellular proliferation 
and differentiation. Upstream genetic alterations, like mutant WT1, result in the 
dysregulation of genes which may contribute to tumorigenesis. Our recent array 
analysis revealed that there are potentially 223 genes that were dysregulated following 
a WT1 mutation. Literature searches, assessment of gene expression pattern(s), and 
functional role(s)) in kidney development and/or cancer focused studies to 21 genes. 
Seven out of the 21 genes, CXXC4, DDR1, FST, HIPK2, MEOX2, MLLT3, and 
PRRX1, were validated by qPCR. The validation data confirmed that these genes 
were dysregulated in WT1-mutant WTs. 
 When I compared the qPCR data to the array data, the dysregulation of their 
gene expression remained consistent and validated the array data. However, some 
the genes, CCCX4, DDR1, HIPK2, and PRRX1, were no longer significantly 
dysregulated in the WT1-mutant tumors. 
 One reason why there was a change in their significance may have resulted 
from the overall technique. Both microarray and qPCR use a reverse transcriptase 
enzyme (RT) that generates a complementary cDNA to the mRNA. However, in 
microarrays, the fluorescent labeled cDNAs are hybridized to their synthetic 
complementary DNAs attached on the microarray slide. The probes used in 
microarrays vary in their length, ranging from 10 to 99 bps. Instead of using a probe to 
hybridize to the complementary cDNA, primers or probes are designed to amplify a 
specific region of the gene (100-200 bps) in qPCR. Depending on the length and 
location of the probes or primers, the assessment of the significance in their gene 
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expression by qPCR may be slightly and/or drastically different from the microarray 
data.   
  Another potential reason for the differences in the degree of gene expression 
change may be due to the cell variation within the WT sample. As mentioned in 
Chapter 1, Wilms tumor could be made up of a mixture of mesenchymal, stromal, and 
epithelial cells, in which the relative proportions of these cells vary broadly in each 
tumor. The RNA isolated from these tumor samples may have one cell type 
predominant over the other cell types residing in the tumor. There is a possibility the 
genes from Table 2.1 are expressed in a specific cell type.  
 Regardless, FST, MEOX2, and MLLT3 were significantly dysregulated in WT1-
mutant WTs. However, the dysregulation of MEOX2 gene expression stood out more 
compared to the other genes. MEOX2 is a member of a novel subclass of the 
homeobox gene super family (131). In humans, MEOX2 is located at chromosomal 
region 7p21, one of the chromosomal regions found altered in WTs (131, 132). 
Homeobox genes, such as MEOX2, regulate cellular growth and differentiation during 
embryonic development and disease progression (133, 134).  
Additionally, MEOX2 is expressed during early embryonic development.  
Between E9-E9.5, Meox2 is expressed in all of the formed somites and in the 
sclerotome, a population of cells lying between the paraxial mesoderm and the limb 
buds (131, 132). At E14.5, Meox2 is expressed in the condensed mesenchyme of the 
kidney. Meox2 gene expression in the developing kidney decreases as the 
metanephric mesenchymal cells differentiate into epithelial structures of the 
developing kidney (42).  
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Because of MEOX2 drastic and significant change in mutant-WT1 WTs, 
biological functions, and embryonic gene expression, MEOX2 is potentially a direct 
candidate downstream gene of WT1 during Wilms tumorigenesis. These suggest that 
there is a transcriptional relationship between WT1 and MEOX2 expression in WT. 
However, more investigation is needed to completely understand the relationship 
between WT1 and MEOX2, such as when and where does the loss of WT1 affect the 
gene expression of MEOX2 during kidney development.  
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Chapter 3: Generation of a Kidney Mesenchymal Cell Line  
Mammalian kidney development results from reciprocal interactions between 
the ureteric bud and the undifferentiated metanephric mesenchyme. Because WT is 
thought to arise from undifferentiated metanephric mesenchyme, it is important to 
study Wilms tumorigenesis during early kidney development. In order to study Wilms 
tumorigenesis at the cellular and molecular level, we intended to use human 
embryonic kidney (HEK) 293 cells, which were transformed with sheared adenovirus 5 
DNA to be cultured and passaged for a long period of time (135). However, 
experiments to determine the effect of the loss of WT1 in the HEK293 cells were not 
feasible, because these cells did not expression high amounts of endogenous WT1 by 
IHC. Therefore, I generated an immortalized undifferentiated kidney mesenchymal cell 
line in which endogenous WT1 is robustly expressed and can be genetically ablated to 
efficiently study the effect of the inactivation of Wt1 on putative downstream target 
genes.  
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Materials and Methods 
Mouse Strains and Breeding 
 The Wt1flox/flox mouse generated and described by Gao et, al, (112) and the 
Immortomouse (CBA;B10-Tg(H2Kb-tsA58)6Kio/Crl) purchased from Charles River 
(Wilmington, MA) were crossed together to obtain Wt1flox/flox; Immorto mice. The 
purpose of this mating cross was to generate a mouse Wt1flox/flox strain that carried the 
Immorto allele for conditional cellular immortalization as described by Jat et. al (136).  
The mating cross consisted of Wt1flox/flox; Immorto female mice and Wt1+/-;Cre-ERTM 
male mice was to generate the following genotypes:Wt1-/flox; Immorto, Wt1+/flox; 
Immorto, Wt1-/flox; Cre-ERTM, Wt1+/flox; Cre-ERTM, Wt1-/flox; Immorto; Cre-ERTM and 
Wt1+/flox; Immorto; Cre-ERTM. The Cre-ERTM inducible model will allow the Cre 
recombinase to recognize the loxP sites around exons 8 and 9 of Wt1, which, in turn, 
will result in a mutant, non-functional WT1 protein (Figure 3.1) in mice with the 
genotype of Wt1-/flox; Immorto; Cre-ERTM. All of the embryos from these crosses will be 
genotype as described below. 
 
Dissociation of the Kidney Mesenchymal Cells 
 The morning of the vaginal plug was defined as E.5. All of the embryos were 
harvested at E13.5 and the kidney rudiments were dissected out. Both of the kidney 
rudiments from each embryo were temporarily stored on ice in 50 µl of 1X trypsin from 
MediaTech (Manassas, VA). Once all the kidneys were dissected out from each 
embryo, the kidney rudiments in the 1X trypsin were placed in the water bath at 37°C 
for 5 minutes. The cells from kidney rudiments were then dissociated into single cell 
suspensions by the use of the 10 µL pipette.   
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Figure 3.1. Schematic Diagram of the Cre-Lox System 
 The 1.55 and 1.75 primers (black arrows) are located around the loxP sites 
around exons 8 and 9 on the floxed allele. Once the Cre-recombinase recognizes 
these loxP sites, an in-frame deletion is created, resulting in the deletion of exons 8 
and 9 to generate a mutant, non-functional WT1 protein.  
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Culturing of the Metanephric Mesenchymal Cells (MMCs)   
 Cells were seeded in a 24-well plate and cultured in permissive conditions: 
Dulbecco's modiﬁed Eagle's medium (DMEM) supplemented with 60 U/mL of 
interferon γ (IFN-γ) from Sigma-Aldrich (St. Louis, MO) and 100 U/mL of antibiotics 
(penicillin, streptomycin, and amphotericin B) (MediaTech), 10% Fetal Bovine Serum 
(FBS), and cultured at 33°C. At this temperature, the temperature sensitive large T-
antigen (TA-g) was produced to ultimately result in the immortalization of the MMCs 
(136). The MMCs were subsequently passaged after enzymatic dissociation in 1X 
trypsin (MediaTech) in DMEM for 5 minutes at 37°C. Once the MMCs reached 40 
passages, they were considered an immortalized cell line (136).  
 
Molecular Characterization of the MMCs 
 A total of 20 clones (the Wt1+/fl; Immorto MMCs) were subcloned by end point 
dilution. Colonies were selected based on their cell morphology that were consistence 
with the established mesenchymal cell morphological traits, such as being  elongated, 
spindle-shaped, and fibroblastic looking  (136). The isolated cells did not resemble 
epithelial cells, which appear to be cuboidal-shaped and well organized.  The F11249 
Wt1-/flox; Immorto; Cre-ERTM, F11254 Wt1-/flox; Immorto; Cre-ERTM, and F12055 Wt1-
/flox; Immorto cell lines were not yet subcloned. Immunocytochemistry analyses of all 
the cell lines indicated whether the cell lines were mesenchymal using two 
mesenchymal markers, Vimentin and Cited1, and an epithelial marker, Cytokeratin.  
The MMC cell lines were seeded onto round, glass cover slips (Fisher) and fixed with 
methanol for 10 minutes and washed off with 1X PBS three times for 10 minutes each. 
Cells were incubated with 10% goat serum in PBS for 1-2 hour at room temperature or 
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overnight at 4°C, depending on the antibody. The fixed cells were then incubated 
overnight at 4°C with either anti-WT1 monoclonal antibody (1:100) (DAKO), anti-MOX2 
monoclonal (1:50) (Santa Cruz), anti-Vimentin monoclonal (1:100), anti-Cited1 (1:100) 
(Fisher) or anti-Cytokeratin monoclonal (1:100) from Sigma-Alrich. After being washed 
three times with PBS, the fixed cells were incubated with conjugated Alexa Fluor 594 
anti-mouse secondary antibody (Invitrogen). The cells on the cover slips were 
mounted in VECTASHIELD mounting media (Vector Laboratories) and images were 
captured by a Leica Epifluorescence/Brightfield Microscope. 
 
Adenovirus Vectors 
 The Cre recombinase and enhanced green fluorescent protein (eGFP) within an 
internal ribosome entry site (IRES) expression cassette (Ad-Cre-IRES-eGFP) 
packaged inside an Adenovirus vector (type 5, DE1/E3) was purchased from Vector 
Biolabs (Philadelphia, PA). The viral infection control was a recombinant human 
adenovirus type 5 expressing eGFP under the control of a cytomegalovirus (CMV) 
promoter (Ad-CMV-GFP) purchased from Vector Biolabs. The purpose of eGFP was 
to monitor the expression of the viral construct after the viral infection. The Adeno-Cre-
eGFP and Adeno-eGFP stocks (titer of 1x1010 PFU/ml) were stored in DMEM with 2% 
Bovine Serum Albumin (BSA), and 2.5% Glycerol. 
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Conditional Ablation of Wt1 in the MMCs 
 After 24hrs of seeding the F11249 Wt1-/flox; Immorto; Cre-ERTM cells or the 
F11254 Wt1-/flox; Immorto; Cre-ERTM cells into a 24-well plate, the cells were treated 
with 1µM of 4-hydroxy tamoxifen (4-OH tamoxifen) for 48hrs. The mutant form of the 
ligand binding domain of the estrogen receptor (ERTM) prevents binding of its natural 
ligand, 17β-estradiol, at normal physiological concentrations, but allows the ERTM 
domain responsive to 4-OH tamoxifen (137-139). The fusion of Cre with ERTM results 
in the ERTM-dependent cytoplasmic sequestration of Cre by Hsp90, which prevents 
Cre-mediated recombination (140, 141). However, binding of 4-OH tamoxifen disrupts 
the interaction Hsp90 that permits access of Cre-ERTM to the nucleus and initiation of 
recombination. The Cre recombinase recognizes the loxP sites flanking exons 8 and 9 
of Wt1. The enzymatic reaction by Cre recombinase results in a mutant, non-functional 
WT1 protein (Figure 3.1).  
 The ablation of Wt1 in the F12055 Wt1-/flox; Immorto MMC cell line was done by 
adenoviral infection that carried the Cre recombinase. The Wt1-/fl; Immorto MMCs were 
infected with 10 multiplicity of infection (MOI) of Adeno Cre for 48 hours. The medium 
was aspirated and replaced with fresh DMEM supplemented with 60 U/mL of IFN-γ 
and 100 U/mL of antibiotics.  
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Genotyping 
 DNA isolated from the MMCs was used for genotyping by PCR amplification 
conditions (Table 3.1) by the primer sets in (Table 3.2). The detection of Wt1-null 
allele was accomplished as described by Kreidberg et, al (43) The presence of the 
Wt1 flox allele was determined using the 1.75/1.55 primer set, in which primers are 
located around the loxP sites flanked around exons 8 and 9. The Cre-ERTM transgene 
was detected by the ZP3-se and ZP3-as primer set (44). The Immorto allele was 
detected by the primer set Immo I and Immo II. The recombined Wt1 flox allele (Wt1∆) 
was detected by PCR amplification using the ckodelF and 1.55 (112). 
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Table 3.1. PCR Conditions for Animal Genotyping 
 
  
Initial 
Denature 
Cycle 
Denature 
Cycle 
Anneal 
Cycle 
Extension Cycles 
Final 
Extension Product Size 
Primer Set               
Wt1-F/PGK 94°C - 3 min 94°C - 45 sec 58°C - 45 sec 72°C - 50 sec 35 72°C - 7 min 250 bps 
1.55/1.75 94°C - 3 min 94°C - 45 sec 58°C - 45 sec 72°C - 50 sec 35 72°C - 7 min 150 and 200 bps 
ckodelF /1.55 94°C - 3 min 94°C - 45 sec 58°C - 45 sec 72°C - 50 sec 35 72°C - 7 min 450 bps 
ZP3-se/ZP3-as 94°C - 3 min 94°C - 45 sec 58°C - 45 sec 72°C - 50 sec 35 72°C - 7 min 600 bps 
Immo I/Immo II 94°C - 4 min 94°C - 30 sec 58°C - 1 min 72°C - 1 min 35 72°C - 7 min 1 kb 
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Table 3.2. Primer Sequences for Animal Genotyping 
Name Sequence (5'-3') 
Wt1-F GTG ACC CCG CAG CTA GCC 
PGK CCA TTT GTC ACG TCC TGC 
1.55 TGC CTA CCC AAT GCT CAT TG 
1.75 GAA ACT GTT TGT AAC GAG AG 
ckodelF GCT AAC ATA TGG GAG ACA TT 
ZP3-se TCC AAT TTA CTG ACC GTA CAC CAA 
ZP3-as CCT GAT CCT GGC AAT TTC GGC TA 
Immo I AGC GCT TGT GTC GCC ATT GTA TTC 
Immo II GTC ACA CCA CAG AAG TAA GGT TCC 
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Results 
Genotyping of the MMCs 
 Genotyping confirmed that clones # 1, 2, 3, 4, 7, 10, 11, 12, 15, 16, and 18 
were Wt1+/fl; Immorto MMCs and F11249 E3 and F11254 E2 cell lines were Wt1-/flox; 
Immorto; Cre-ERTM MMCs (Figure 3.2). Cell line F11254 E3 was Wt1fl/fl; Immorto; Cre-
ERTM, and F12055 was Wt1-/fl; Immorto (Figure 3.5).  
 Two of the cell lines, F11249 Wt1-/flox; Immorto; Cre-ERTM and F11254 Wt1-/flox; 
Immorto; Cre-ERTM were tamoxifen-inducible cell lines, which Wt1 can be genetically 
ablated by the Cre-recombinase. By PCR analysis, the ablation of Wt1 occurred after 
48 and 72 hrs as shown in Figure 3.3. However, the ablation of Wt1 in these cells was 
incomplete, as indicated by the residual presence of the floxed allele. 
 The ablation of Wt1 in the F12055 Wt1-/flox; Immorto MMCs cell line was 
achieved by adenoviral infection. As shown in Figure 3.5, GFP positive cells indicated 
that the cells were successfully infected by the adenovirus. PCR analysis confirmed 
the presence of the Cre-ERTM transgene and demonstrated the recombination of the 
Wt1fl allele 48 hrs after of the adenoviral infection (Figure 3.5). Most important, the 
ablation of Wt1 after the adeno-viral infection of Cre-recombinase was complete; the 
floxed allele was no longer present (Figure 3.5).  
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Figure 3.2. PCR Analyses of the MMCs using Wt1-F/PGK, 1.55/1.75, ZP3 se/ZP3 as, and Immo I/Immo II primer 
sets 
 Cells isolated from E13.5 embryos were genotyped using the established primer sets to detect the Wt1 null allele, 
floxed allele, CreERTM allele, and the Immorto allele (Table 3.1). Genotypes are shown to the right.  
 
Lane# MMCs DNA Samples Genotype 
1 F736 E6 clone#1 Wt1+/fl; Immorto 
2 F736 E6 clone#2 Wt1+/fl; Immorto 
3 F736 E6 clone#3 Wt1+/fl; Immorto 
4 F736 E6 clone#4 Wt1+/fl; Immorto 
5 F736 E6 clone#7 Wt1+/fl; Immorto 
6 F736 E6 clone#10 Wt1+/fl; Immorto 
7 F736 E6 clone#11 Wt1+/fl; Immorto 
8 F736 E6 clone#12 Wt1+/fl; Immorto 
9 F736 E6 clone#15 Wt1+/fl; Immorto 
10 F736 E6 clone#16 Wt1+/fl; Immorto 
11 F736 E6 clone#18 Wt1+/fl; Immorto 
12 F11249 E3 #1 (15) Wt1-/flox; Immorto; Cre-ERTM 
13 F11249 E3 #2 (14) Wt1-/flox; Immorto; Cre-ERTM 
14 F11254 E2 #5 (15) Wt1-/flox; Immorto; Cre-ERTM 
15 F11254 E3 #2 (16) Wt1-/flox; Immorto; Cre-ERTM 
16 F11254 E3 #5 (17) Wt1-/flox; Immorto; Cre-ERTM 
17 #52 (Fl allele Control) Wt1 fl/fl 
18 #70 (∆ allele Control) Wt1 -/∆ 
19 #20 (Cre(-) Control) Wt1 +/+ 
20 dH2O -  
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Figure 3.3. Ablation of Wt1 by Tamoxifen Treatment 
 As shown in duplicates, F11249 E3 Wt1-/fl; Immorto; CreTM cell line was treated with 1 µM of Tamoxifen for 48 hrs 
and at 72 hrs the recombined Wt1Δ allele is detected. However, the floxed allele was still present, which indicated only 
partial ablation of Wt1.   
Lane # Description 
1 48 hrs Untreated Set 1 
2 48 hrs 1 µM 4-OH-Tamoxifen Set 1 
3 48 hrs Untreated Set 2 
4 48 hrs 1 µM 4-OH-Tamoxifen Set 2 
5 72hrs Untreated Set 1 
6 72 hrs 1 µM 4-OH-Tamoxifen Set 1 
7 72 hrs Untreated Set 2 
8 72 hrs 1 µM 4-OH-Tamoxifen Set 2 
9 dH2O 
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Figure 3.4. Viral Infection of Adeno-Cre-GFP in the F12055 Wt1-/flox; Immorto 
MMC cell line   
 The top panel of images was taken by Differential Interference Contrast 
microscopy (DIC) and the middle panel of images was taken with a GFP-FITC (GFP-
fluorescein isothiocyanate) filter to detect the excitation at 519 nanometers in the 
green region to indicate the cells that have been infected and expressed GFP. All of 
the images were taken at 20X magnification. The lower panel of images merged DIC 
and FITC images together to determine the number of cells that were infected by the 
adenovirus. NTC – Non Treated Cells 
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Figure 3.5. PCR Analyses of the Ablation of Wt1 in the F12055 Wt1-/flox; Immorto 
MMC cell line infected by Adeno-Cre-eGFP or Adeno-eGFP 
 The complete ablation of Wt1 was detected after 48hrs. All the cells were 
confirmed to have the Wt1 null allele (yellow arrow) and the recombined allele (red 
arrow) by using the primers in Table 3.1. (C=Cells infected with Cre and eGFP 
adenovirus, G= Cells infected with eGFP only, and N= Non-Treated cells) 
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Molecular Characterization of the MMCs 
 All of the cells displayed in Table 3.3 reached passage 40 and were considered 
immortalized cell lines. The wild type Wt1+/fl; Immorto MMCs were sub-cloned based 
on their cell morphology. Ten clones of Wt1+/fl; Immorto MMCs were generated, and 
were vimentin positive and cytokeratin negative (Appendix Figure 1). Of the 10 
clones, Clone# 10 expressed more of both Wt1 and Meox2 (Figure 3.6 A). Wt1-/flox; 
Immorto cell line, F12055, expressed Wt1 and Meox2 similar to Clone #10 (Figure 3.6 
B).  An established mesenchymal cell marker, Cbp/p300-interacting transactivator 1 
(Cited1), was used to ensure that the MMCs were derived from the cap mesenchyme. 
Cited1 is known to be  specifically expressed in the condensed cap mensenchyme 
with no expression in the clefts between the ureteric bud or the surrounding stromal 
mesenchyme (142, 143). As shown in Figure 3.7, Wt1+/flox; Immorto and  
F12055 Wt1-/flox; Immorto MMCs were positive for Cited1 further indicating the 
mesenchymal status of the cell lines.  
 The Wt1-/flox; Immorto; CreERTM (F11249 E3 and F11254 E2) and the Wt1-/flox; 
Immorto cell lines have not been sub-cloned based on their cell morphology. These 
cells are still a heterogeneous population of vimentin and cytokeratin positive cells. In 
addition, Wt1-/flox; Immorto; CreERTM (F11249 E3 and F11254 E2) did not express Wt1 
(Appendix Figure 2).  
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Table 3.3 MMCs Cell Lines Derived from E13.5 Kidney Rudiments 
Wt1, Meox2, Vimentin, Cited1, and Cytokeratin were the markers used to determine whether the cells were 
mesenchymal.  
Cell Line Genotype Wt1 Meox2 Vimentin Cited1 Cytokeratin 
Clone # 1 Wt1 +/fl; Immorto + NT + NT - 
Clone # 2 Wt1 +/fl; Immorto + weak NT + NT - 
Clone # 3 Wt1 +/fl; Immorto + weak NT + NT - 
Clone # 4 Wt1 +/fl; Immorto + NT + NT - 
Clone # 5 Wt1 +/fl; Immorto - NT + NT - 
Clone #7 Wt1 +/fl; Immorto + NT + NT - 
Clone # 8 Wt1 +/fl; Immorto + weak NT + NT - 
Clone # 10 Wt1 +/fl; Immorto + + + + - 
Clone # 11 Wt1 +/fl; Immorto + weak NT + NT - 
Clone # 15 Wt1 +/fl; Immorto + weak NT + NT - 
F11249 E3 Wt1 -/fl; Immorto; CreERTM - NT + NT +* 
F11254 E2 Wt1 -/fl; Immorto; CreERTM - NT + NT +* 
F12055 Wt1 -/fl; Immorto + + + + +* 
 
(+) - Expressed the marker 
(-) - Did not express the marker 
Weak – The intensity of the IF staining was weak compared to the control cell line (MCF-7 cells).  
NT- Not Tested 
* - The cell line was not subcloned.  
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Figure 3.6. IF Images of the Generated MMCs from E13.5 Kidney Rudiments 
 A. The top panel of images is Clone #10 Wt1+/flox; Immorto MMC cell line and 
the bottom panel of images is the control, MCF-7 cell line. As shown, Clone #10 
Wt1+/flox; Immorto MMCs were WT1, MEOX2, vimentin positive and cytokeratin 
negative. DAPI (blue) stains the nucleus. 
 B. The top panel of images is F12055 Wt1-/flox; Immorto MMC cell line and the 
bottom panel of images is the control, MCF-7 cell line. F12055 Wt1-/flox; Immorto MMC 
cell line expressed both WT1 and MEOX2. Because the F12055 Wt1-/flox; Immorto 
MMC cell line were not sub-cloned, it is presently a heterogeneous population of 
vimentin and cytokeratin positive cells.  
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Figure 3.7. MMCs are Positive for Cited1: Biological Marker for Condensed Cap 
Mesenchyme 
 Clone #10 Wt1+/fl; Immorto MMCs (top panel) and the F12055 E4 Wt1-/fl; 
Immorto (bottom panel) were positive for CITED1, which confirmed that these cells 
were isolated from the condensed cap mesenchyme. DAPI (blue) stains the nucleus. 
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Discussion 
 The HEK 293 cell line was the first transformed human cell line. Since these 
cells were isolated from the kidney, I thought it would serve a good cellular model to 
study the effect of the loss of Wt1 on the gene expression of Meox2. Hence, I 
proposed to manipulate the gene expression of Wt1 either by siRNA and/or shRNA to 
assess the effect on Meox2 gene expression. However, these cells were more 
epithelialized cells and they did not express a robust amount of Wt1.  Therefore, I 
generated several Wt1 kidney mesenchymal cell lines: wildtype Wt1 MMCs (Wt1 +/fl; 
Immorto) and the mutant Wt1 MMCs F11249 E3 and F11254 E2 (Wtl-/fl; Immorto; 
CreTM) and F12055 (Wt1-/fl; Immorto). 
 After the molecular characterization of all the cell lines (Table 3.2), I chose  two 
cell lines, Clone #10 Wt1+/flox; Immorto cell line and F12055 Wt1-/flox; Immorto cell line 
for my experiments to study the effect of the inactivation of Wt1 on the gene 
expression of Meox2 in vitro. Both of these cell lines displayed mesenchymal 
morphological traits of being elongated, spindle-shaped, and fibroblastic looking.  
Additionally, the total ablation of Wt1 was achieved in the F12055 Wt1-/fl; Immorto cell 
line after infection with Adeno-Cre-GFP. By using these molecular tools, we can 
understand how a Wt1 mutation effects Meox2 and other potential downstream genes 
in kidney mesenchymal cells that may contribute to Wilms tumorigenesis. We can 
assess WT1-ablated cells for tumorigenic phenotypes, such as increased cellular 
proliferation, inhibition of apoptosis, disruptions in cellular adhesion and migration. 
Furthermore, the cell lines generated were not just limited for the purpose of Wilms 
tumorigenesis, but can be used to experimentally study the loss of Wt1 in other kidney 
cancers and during kidney development.  
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Chapter 4: Inactivation of Wt1 effects the Gene Expression of Meox2 during 
Kidney Development 
 Mesenchyme homeobox 2 (MEOX2), formally known as GAX and MOX2, was 
one of the seven genes from the prioritized microarray data and was significantly up 
regulated by 19-fold in the WT1 mutant Wilms tumors. MEOX2 is a member of a novel 
subclass of the homeobox gene super family which is located at chromosomal region 
7p21 in humans and on chromosome 12 in mice (131, 132). MEOX2 consists of three 
exons and two introns. It also contains a nuclear localization signaling (NLS) as shown 
in Figure 4.1 A (131). Homeobox genes like MEOX2 encode homeodomains that 
correspond to a 60 amino acid helix-turn-helix DNA binding region, located near the C-
terminus of the protein (Figure 4.1 B) (131, 133, 144). Homeobox proteins localize to 
the nucleus and are transcription factors which regulate the expression of lineage 
specific genes which, in turn, control cellular and organ differentiation (145).  
 MEOX2 is expressed during early embryonic development.  Between E9-E9.5, 
Meox2 is expressed in all of the formed somites and in the sclerotome, a population of 
cells lying between the paraxial mesoderm and the limb buds (131, 132). At E14.5, 
Meox2 is expressed in the condensed mesenchyme of the kidney (Figure 4.2). Meox2 
gene expression in the developing kidney decreases as the metanephric 
mesenchymal cells differentiated into epithelial structures of the developing kidney 
(42). The embryonic gene expression of Meox2 suggests that it has a specific role 
during development.   
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Figure 4.1. Representation of Meox2 Gene and Protein Sequence 
 A. Meox2 is a homeobox gene that contains 3 exons (light blue) and 2 large 
introns. The homeobox domain (dark blue) is encoded by exons 2 and 3. 
 B. Amino acid sequence of Meox2 gene product. The homeodomain 
(highlighted in yellow) starts in exon2 at position 187 and ends in exon 3 at position 
245. The NLS sequence (underlined in red) is located within exon 3.  
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Figure 4.2. Meox2 Gene Expression in E14.5 Mouse 
 At E14.5, Meox2 is expressed in the condensed metanephric mesenchyme 
(Adapted from (146)). 
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In normal mouse mammary epithelial NMuMG cells, Meox2  expression has 
been shown to be regulated by Tgf-β1 (147). After 16-24 hrs of Tgf-β1 stimulation, the 
gene expression of Meox2 increased 2-8X in NMuMG cells. Dominant-negative 
mutants of Smad3 and Smad4 blocked the induction of Meox2, further indicating that 
the regulation of Meox2 was dependent on the stimulation of Tgf-β1(147). 
Furthermore, the endogenous expression of Meox2 by Tgf-β1 inhibits proliferation by 
inducing p21 in the NMuMG cells (147). However, these data do not demonstrate that 
Meox2 expression is dependent only by Tgf-β1 stimulation and whether the regulation 
of Meox2 is cell specific. Other genes throughout development could regulate Meox2. 
MEOX2 is upregulated in the WT1 mutant WTs, and Meox2 and Wt1 are both 
expressed during kidney development in the condensed mesenchyme. These data 
suggest that Wt1 may regulate the gene expression of Meox2 during developing 
kidney.  
In order to assess whether there are any predicted WT1 binding sites in 
MEOX2, the Match™ web-based tool from the BIOBASE Biological Database was 
used to identify transcription factor binding sites in the MEOX2 gene by a weight 
matrix search. The Match™ web-based tool was able to identify one predicted Wt1 
binding site (cCCTCCccc) within the first intron of MEOX2 suggesting that WT1 may 
regulate MEOX2.  Having identified a putative WT1 binding site within the MEOX2 
gene, I sought to determine whether modulation of Wt1 expression resulted in a 
corresponding change in Meox2 expression in vivo in developing mouse kidney and 
also in the kidney mesenchymal cell lines. I further sought to determine the role, if any, 
of Tgf-β1 in regulating Meox2 expression in these cells. Moreover, I investigated the 
phenotypic effect of Wt1 ablation in this experimental system. Additionally, I 
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investigated whether the inactivation of Wt1 affects the gene expression of the 
established regulator, Tgf-β1, of Meox2. The dysregulation of p21 and Itgb5 resulting 
from the upregulation of Meox2 was also assessed within this study.   
 Within this chapter, I have demonstrated that following the ablation of Wt1 in 
E13.5 kidney rudiments and in the kidney mesenchymal cell lines, Meox2 expression 
was upregulated. Data revealed that Tgf-β1 did not contribute to the dysregulation of 
Meox2. Moreover, the established downstream genes of Meox2 (p21 and Itgb5) were 
dysregulated after the upregulated of Meox2 in the kidney mesenchymal cells. A novel 
phenotype was observed in the presence of a Wt1 mutation and the upregulation of 
Meox2; the cells decreased in cellular growth and loss the ability to adhere to the cell 
culture plates. Overall, these significant data further supported my hypothesis that the 
gene expression of Meox2 is upregulated both in vivo and in vitro, following a Wt1 
mutation during early kidney development.   
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Materials and Methods 
Mouse Strains  
 Refer to Chapter 3 – Materials and Methods – Mouse Strains. 
 
In Vivo Ablation of Wt1 
 The Wt1-/flox mouse model generated and described by Gao et, al, was used to 
genetically ablate Wt1 exons eight and nine in vivo (112). Crosses were set up with 
the females’ genotype Wt1flox/flox and the males’ genotype Wt1+/-; Cre-ERTM. At E11.5, 
the females were injected with 3mg of Tamoxifen to ablate Wt1.  
 
RNA Isolation from Embryonic Kidney Tissue 
 Kidneys were dissected from embryos at E13.5 and were placed into 1mL 
TRIzol purchased from Invitrogen (Carlsbad, CA). The tissues were completely 
homogenized in the TRIzol and precipitated by isopropanol. The RNA was rinsed off 
with 70% ethanol. The RNA pellet was resuspended in RNase-free distilled water. The 
RNA was treated with 1 µl of DNase 1 (Applied Biosystems) for 30 minutes to remove 
any traces of DNA contamination.  
 
Genotyping of the Kidney Rudiments 
 Limbs of the dissected E13.5 embryos were used to extract DNA. PCR 
genotyping as previously described in Chapter 3. The PCR conditions are displayed in 
Table 3.1. The primer sets used for the genotyping are displayed in Table 3.2.  
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In Vitro Ablation of Wt1 in the MMCs 
 Immediately after seeding into 60mm plates, F12055 MMCs were infected with 
10 multiplicity of infection (MOI) of Adeno Cre for 48 hours. The medium was aspirated 
and replaced with fresh DMEM supplemented with 60 U/mL of IFN-γ and 100 U/mL of 
antibiotics. As a control, a second plate of cells was infected with Adeno GFP of 10 
MOI. The recombined allele was detected by PCR as described in Chapter 3 in Table 
3.1. 
 
RNA Isolation from the Infected MMCs 
 After each time point (48, 72, and 96 hours), cells were harvested, centrifuged 
at 7500 revolutions per minute (rpm) for 5 minutes, and resuspended in TRIzol to 
isolate RNA.. A phenol-chloroform extraction was done to remove the residual salt in 
the RNA sample. The RNA was re-precipitated by 5M Ammonium Acetate, Linear 
Acrylamide, and 100% ethanol at -20C. The RNA pellet was resuspend in RNase-free 
distilled water. The NanoDrop spectrophotometer from Thermo Scientific (Wilmington, 
DE) was used to quantify the RNA. RNA samples were stored at -80°C. 
 
qPCR  
 cDNAs were prepared from E13.5 kidney and MMCs RNA by reverse 
transcribing 1 µg of total RNA as described in Chapter 2 Materials and Methods. The 
primer sets for Wt1, Meox2, Tgf-β1, Smad3, p21, and intergrin β5 are displayed in 
Table 4.1. 
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Table 4.1. Primer Sets designed by Primer Express v.3 Software for the qPCR 
analysis using cDNA from E13.5 kidney and MMCs 
 
Name Sequence (5'-3') 
Wt1 F CAAGGACTGCGAGAGAAGGTTT 
Wt1 R TGGTGTGGGTCTTCAGATGGT 
Meox2 F GCTGTCACCCGCAGACGTA 
Meox2 R AATCTGAGCTGTCGCTTTTCCT 
Tgf-β1 F AAACGGAAGCGCATCGAA 
Tgf-β1 R TGGCGAGCCTTAGTTTGG 
Smad3 F GGAATGCAGCCGTGGAAC 
Smad 3 R GACCTCCCCTCCGATGTAGTAGA 
p21 F ACGTGGCCTTGTCGCTGTC 
p21 R AATCTGCGCTTGGAGTGATAG 
Itgb5 F AGGCTGGGACGTCATTCAGA 
Itgb5 R GCGAACCTGTAGCTGAAGGT 
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Results 
In Vivo Ablation of Wt1 during Early Kidney Development 
The Cre-mediated ablation of Wt1 did occur, which resulted in the recombined 
allele produced by the CKO primer set as shown in Figure 4.3. However, the ablation 
of Wt1 did not occur in all the cells, because the floxed allele was still present after the 
kidney rudiments were genotyped by PCR as described in Chapter 3 (Figure 4.3).  
However, Wt1 was genetically knocked out in ~70% (.0004) of cells at E13.5 and 
resulted in the increase of Meox2 relative gene expression by 2X (.018) as shown in 
Figure 4.4.  
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Figure 4.3. PCR Analyses of the E13.5 Kidney Rudiments after the in vivo Ablation of Wt1 
 The E13.5 embryos were genotyped after 48 hrs of tamoxifen treatment to ablate Wt1. Genotypes of these embryos are 
to the right.   
Lane # Genotype Lane # Genotype 
1 Wt1-/fl 10 Wt1-/fl;CreTM 
2 Wt1+/fl;CreTM 11 Wt1-/fl 
3 Wt1+/fl;CreTM 12 Wt1-/fl;CreTM 
4 Wt1-/fl 13 Wt1-/fl;CreTM 
5 Wt1+/fl 14 Wt1-/fl;CreTM 
6 Wt1-/fl 15 Wt1-/fl 
7 Wt1-/fl 16 Wt1+/fl 
8 Wt1+/fl;CreTM 17 (+)  Wt1-/fl;CreTM 
9 Wt1+/fl;CreTM 18 (-) ddH2O  
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Figure 4.4. Meox2 Gene Expression after the in vivo Ablation of Wt1 
 In this graph, the y-axis indicates the gene expression Wt1 and Meox2 in the 
Wt1-/∆ kidney rudiments relative to the Wt1+/∆ kidney rudiments. The blue bars 
represent the control samples Wt1+/fl; CreTM (n=4) and the red bars represents the 
mutant samples Wt1-/fl; CreTM (n=4). After the ablation, Wt1 is knocked down by 70% 
(.0004) and Meox2 gene expression increased by 2X (.018). 
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Downstream Effects Due to the In Vitro Ablation of Wt1  
 In order to assess the loss of Wt1 on the gene expression of Meox2, other 
potential downstream genes, and tumorigenic phenotypes, such as over cellular 
proliferation, inhibition of apoptosis, disruptions in cellular adhesion and migration, Wt1 
was genetically knocked down in the generated F12055 Wt1-/fl; Immorto kidney 
mesenchymal cells by adenoviral infection as described in the Materials and 
Methods. As shown in Figure 4.6, Wt1 was knocked down by ~90% after 48 hrs of 
infection by qPCR analysis. After 48hrs and 72hrs of infection, there was no significant 
dysregulation of Meox2. After 96 hrs of infection, the gene expression of Meox2 
significantly increased by 61X (0.001) as shown in Figure 4.5.  
 It has been reported that the Tgf-β/Smad pathway mediates the activation of 
Meox2 expression by Tgf-β1 (147). Additionally, a dominant negative mutant Smad3 
had an effect on the on blocking the endogenous Tgf-β/Smad signaling, which resulted 
in the late induction of Meox2 mRNA levels (147). Thus, Tgf-β1 and Smad3 are known 
to be involved induction of Meox2 expression. After 48 hrs of the knockdown of Wt1, 
Tgf-β1 had a relative gene expression of ~2X (0.039) (Figure 4.6). However after 72 
hrs and 96 hrs of the knockdown of Wt1, Tgf-β1 expression was knocked down by 
approximately 40% as shown in Figure 4.6. For Smad3, its expression was at 1.58X 
(0.243) after 48 hrs of the knockdown of Wt1. Smad3 expression fluctuated between 
72 hrs and 96 hrs. After 72 hrs, Smad3 expression was knocked down approximately 
50%. After 96 hrs after the knockdown of Wt1, Smad3 expression increased to 1.23 
(0.799). Overall, this data indicated that the loss of Wt1 has an effect on Tgf-β1 
expression, but not on Smad3 expression. Moreover, it also suggest that the 
upregulation of Meox2 expression was due to the loss of Wt1. 
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Figure 4.5. Meox2 is Upregulated following the in vitro Ablation of Wt1 
 In the figure above, the y-axis indicates the gene expression Wt1 (blue) and Meox2 (red) in the Wt1-/∆; Immorto MMCs 
relative to the Wt1-/fl; Immorto MMCs. The x-axis is a table that provides the values of how much Wt1 and Meox2 were relatively 
expressed. The ablation of Wt1 in MMCs resulted in the upregulation of Meox2 expression after 96 hrs.
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Figure 4.6. The Effect of Loss of Wt1 on Tgf-β1 and Smad3 Gene Expression 
 In the figure above, the y-axis indicates the gene expression Wt1 (blue), Tgfβ-1 (red), and Smad3 (pink) in the Wt1-/∆; 
Immorto MMCs relative to the Wt1-/fl; Immorto MMCs. The x-axis is a table that provides the values of how much Wt1, Tgf-β1, 
and Smad3 were relatively expressed after the ablation of Wt1 in the MMCs.  
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Dysregulation of Meox2 Targeted Genes and Cellular Phenotype   
 I have demonstrated that MEOX2 is upregulated following the ablation of WT1 
in WTs, during early kidney development, and in kidney mesenchymal cells. It is 
known that the upregulation of Meox2 results in the induction of p21 and the 
repression of Itgb5 (145, 148-150) (151).  By qPCR analysis, after 96 hrs of infection, 
the upregulation of Meox2 in MMC cells resulted in the significant induction of p21 
(0.0002) and decreased the expression of Itgb5 (0.01) (Figure 4.7). In addition to this, 
an abnormal cellular phenotype was observed. As shown in Figure 4.8, the number of 
the Wt1-/∆; Immorto MMCs cells on the plate appeared to be less after 72 hrs of 
infection compared to the control cells. After 96 hrs of infection, there was a significant 
decrease in the number of adherent cells and an increase of floating cells.  
 To determine whether these cells were apoptotic, the floating cells were stained 
with Trypan blue reagent which stains dead cells. Surprisingly, the majority of the 
floating cells were viable. In Figure 4.9, the number of Wt1-/∆; Immorto MMCs was 
compared to the number of the Wt1-/fl; Immorto MMCs by counting the number of cells 
after they were stained with the Trypan blue reagent.  The total number of Wt1-/∆; 
Immorto MMCs started to decrease after 72hrs (0.080) (Figure 4.9). After 96 hrs of 
infection, there was a significant decrease in the total number of Wt1-/∆; Immorto 
MMCs compared to the control (0.044), which ~40% of the Wt1-/∆; Immorto MMCs total 
number of cells were viable and in suspension (Figure 4.9).  
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Figure 4.7. Induction of p21 and the Repressiom of Itgb5 
 In the figure above, the y-axis indicates the gene expression Meox2 (red), p21 (black), and Itgb5 (gray) in the Wt1-/∆; 
Immorto MMCs relative to the Wt1-/fl; Immorto MMCs. The x-axis is a table that provides the values of how much Meox2, p21, 
and Itgb5 were relatively expressed. After 96hrs of Wt1 ablation, the overexpression of Meox2 resulted in the significant 
induction of p21 (0.0002) and the knockdown of Itgb5 (0.01).  
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Figure 4.8. The Effect of Wt1 Ablation in Wt1-/flox; Immorto MMCs: Visual 
Observation in Decrease Cell Number and Loss of Cell Adhesion 
 As shown above, the top panel of images is infected cells with Adeno Cre   
(Wt1-/∆; Immorto MMCs) and the bottom panel of images is infected cells with Adeno 
GFP (Wt1-/fl; Immorto MMCs) at different time points.  
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Figure 4.9. The effect of Wt1 Ablation in Wt1-/flox; Immorto MMCs: Quantification 
of Cell Proliferation and Adhesion 
 In this figure, the red lines indicate the mutant, Wt1-/∆; Immorto MMCs and the 
blue lines indicate the Wt1-/fl; Immorto MMCs (control). Lines with circle indicate the 
total number of cells, lines with triangles indicate the number of adherent cells, and 
lines with squares indicate the number of suspended cells at 48 hrs, 72 hrs, and 96 
hrs. 
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Discussion 
 The functional role of Meox2 has been studied in vascular smooth muscle cells 
(VSMCs), endothelial cells, and cardiomyocytes. Within these cell types, Meox2 
induces the cyclin-dependent kinase inhibitor, p21 (145, 148-150).  Moreover, Meox2 
has shown to induce apoptosis in VSMCs (150). Meox2 specifically repressed β3 and 
β5 integrins in VSMC and may lead to the disruption of integrin-regulated signaling 
pathways (151). In endothelial cells, Meox2 inhibits cellular proliferation and 
endothelial cell tube formation (152). All together, Meox2 regulates genes that are 
involved in cellular proliferation and cell adhesion. However, the role of Meox2 has not 
been extensively studied during kidney development, in particular, kidney 
mesenchymal cells.  
  According to the literature, the mediated-regulation of Meox2 results from the 
stimulation of Tgf-β1 (147). It is known that TGF-β inhibits cellular proliferation of 
specific cells types and mutated in various human cancers; TGF-β has the functional 
role of being a tumor suppressors (153-155). TGF-β2 and TGF-β3  were  up-regulated 
in mutant WTs in the microarray data (156). Could it be that during kidney 
development, TGF-β2 and TGF-β3 were transcriptionally repressed by WT1? During 
Wilms tumorigenesis, could the loss of WT1 upregulate the gene expression of TGF-
β2 and TGF-β3 which resulted in the upregulation of MEOX2? TGF-β1 was the only 
TGF-β gene assessed on the array. Therefore, the other TGF-β genes need to be 
assessed following WT1 mutation as discussed in Chapter 5. 
  Because Meox2 was expressed at high levels in WTs and during kidney 
development following a Wt1 mutation, it may play a role as an oncogene, which 
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would cause cells to survive and overproliferate. The overexpression of Meox2 
following a Wt1 mutation resulted in the induction of p21 and the downregulation of 
Itgb5. In addition, there was a decrease in cell number and an increase in the number 
of floating cells which goes against the concept of an oncogenic phenotype. However, 
the floating cells were viable and potentially still growing. If these cells were 
considered tumorigenic and remain viable and proliferative, they could metastasize 
throughout the body, which would define Meox2 as an oncogene. However, we do not 
know whether this cellular phenotype was due to the overexpression of Meox2 or from 
the loss of Wt1.  
 Overall, my data supports my hypothesis that the upregulation of Meox2 is Wt1-
dependent during early kidney development (in vivo studies), especially in the 
condensed mesenchyme (in vitro studies).  The dysregulation of downstream targeted 
genes of Meox2 followed the upregulation of Meox2 in the MMCs. A novel cellular 
phenotype was discovered, in which the cells decreased in number and lose their 
ability to adhere after the ablation of Wt1 and/or the upregulation of Meox2. Of course 
there needs to be more analyses done to further investigate the effect of the loss of 
Wt1 on Meox2 gene expression and the role of over expressed Meox2 in the kidney 
mesenchymal cells as discussed in Chapter 5.  
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Chapter 5: Conclusions and Future Directions  
 Conclusions 
Wilms tumor is a childhood cancer of the kidney that represents approximately 
95% of all pediatric kidney tumors and accounts for 6% of all pediatric cancers (1-4). 
The classic histology of WTs in both humans and mice is triphasic, which consist of 
mesenchymal, stromal, and epithelial cells. The data from WT histology suggest that 
there was a disruption during cellular differentiation of the mesenchymal cells during 
early kidney development. Most of our understanding of the association between WTs 
and kidney development derived from the investigation of WT1 and the histology of 
WTs. However, the role of WT1 during Wilms tumorigenesis is unclear. WT1 is a 
transcriptional factor that is known to activate or repress genes involved in cellular 
proliferation, differentiation, apoptosis, cellular migration, and cellular adhesion. 
Therefore, it is hypothesized that the inactivation of WT1 has a reverse effect on 
downstream genes that are involved in cellular proliferation, differentiation, apoptosis, 
cellular migration, and cellular adhesion that potentially lead to Wilms tumorigenesis.  
 Recently, an Affymetrix GeneChip Human Genome Array was conducted with 
human with WT1-wildtype and WT1-mutant WTs. Numerous genes were dysregulated 
in WT1-mutant WTs, which MEOX2 was one of the significantly dysregulated genes 
upregulated by 19X in WT1-mutant tumors. MEOX2 was validated by qPCR and 
remained significantly upregulated in WT1-mutant tumor by 41X. 
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In order to test the hypothesis that Meox2 is upregulated in a Wt1-dependent 
manner, Wt1 was genetically ablated. A qPCR analysis was conducted comparing the 
control kidneys to the Wt1 ablated kidneys, which resulted in the upregulation of 
Meox2.  Since Wt1 and Meox2 were both expressed in the mesenchyme, a kidney 
mesenchymal cells line was generated in which Wt1 could be genetically ablated with 
Cre recombinase to determine the effect of Wt1 mutation on Meox2 gene expression. 
Once again, the effect of the ablation of Wt1 resulted in the significant upregulation of 
Meox2. The significant upregulation of Meox2 following a Wt1 mutation, specifically in 
the mesenchyme, further supported the hypothesis that the upregulation of Meox2 is 
Wt1-dependent. The inactivation of Wt1 and/or the upregulation of Meox2 induced 
p21, repressed Itgb5and revealed a unique cellular phenotype in which the cells 
displayed a loss of cellular adhesion and a decrease in cellular growth. It is not certain 
whether the induction of p21 and the repression of Itgb5 are the cause of the cellular 
phenotype. However, there is more to investigate how the loss of Wt1 leads to the 
formation of WT by first further investigating the actual functional role of Meox2 during 
kidney development as later discussed. By further studying the dysregulated genes in 
WTs, such as MEOX2, we can develop therapeutic strategies to prevent and improve 
treating Wilms tumors. Additionally, we can understand how the remaining 80% of 
WTs were formed independent of WT1 mutation.    
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Future Directions 
Even though the upregulation of MEOX2 expression following a WT1 mutation 
was quantitatively assessed in WTs during developing kidney at E13.5 and in the 
mesenchymal cell line, there are still gaps remaining in understanding the mechanistic 
relationship between WT1 protein and MEOX2 gene.  In order to determine how the 
Wt1 protein and Meox2 gene interact, directly or indirectly, a Chromatin 
Immunnoprecipitation (ChIP) sequence would provide evidence that Wt1 is directly 
regulating the gene expression of Meox2.  
 At E13.5, Meox2 was significantly upregulated in the kidney rudiments following 
Wt1 ablation. To determine whether the loss of Wt1 affected Meox2 gene expression 
throughout kidney development, more developmental time points are required. These 
studies will provide data to specifically show when and where the upregulation of 
Meox2 occur during kidney development after the loss of Wt1.  
 It has been reported that the TGF-β/Smad pathway positively mediates the 
gene expression of Meox2. I sought to determine whether Wt1 regulates Meox2 
expression by altering the TGF-β/Smad pathway. According to my data, the gene 
expression of Tgf-β1 was downregulated when Wt1 was ablated in the mesenchymal 
cells. According to our microarray data, TGF-β2 and TGF-β3 were both upregulated in 
the Wt1-mutant WTs. Thus, TGF-β2 and TGF-β3 could also regulate the gene 
expression of MEOX2.  For future experiments, a qPCR will be conducted to analyze 
whether Wt1 dysregulates Tgf-β2 or Tgf-β3 in kidney rudiments and in the MMC cell 
lines that could lead to upregulation of Meox2. If either of these Tgf-β proteins are 
upregulated after the ablation of Wt1, it would suggest two possibilities: 1) that Wt1 
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represses the expression Tgf-β2 and Tgf-β3 and/or 2) that the regulation of Meox2 is 
dependent on the isoforms of Tgf-β proteins. The combination of the two possibilities 
would suggest that Wt1 is upstream and transcriptionally regulates the TGF-β/Smad 
pathway and Meox2 expression.  
 The ablation of Wt1 is known to slightly induce apoptosis during kidney 
development (157). In the MMCs, the ablation of Wt1 after 96hrs resulted in the 
significant increase of Meox2, decrease of adhesive cells, and the decrease in cell 
growth. The floating cells were viable, however, they could be undergoing early 
induction of apoptosis. In the future, this experiment needs to be repeated and 
extended to determine whether these cells will eventually become apoptotic by 
Fluorescence Activated Cell Sorting (FACS) or transferase dUTP nick end labeling 
(TUNEL) assay. In addition, testing different cellular adhesion coatings, such as 
gelatin, collagen, fibronectin, poly-D-lysine, or poly-L-lysine, with Wt1 ablated cells 
may reduce the loss of cellular adhesion. 
 In order to assess whether the decrease in cell growth and loss of cellular 
adhesion was solely achieved by the upregulation of Meox2, future experiments would 
also include overexpressing Meox2 independently of Wt1. A construct with a pCMV 
promoter that overexpresses full-length Meox2 has been generated in the lab. The 
pCMV-Meox2 construct could be transiently transfected into a wildtype Wt1+/fl; Immorto 
MMCs cell line to determine whether these phenotypes resulted solely from the 
overexpression of Meox2.  
 These future directions will set the stage to study the relationship between Wt1 
and Meox2 during kidney development, to understand the role of Meox2 during kidney 
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development, and to develop strategies to reverse the phenotypes, such as the 
dysregulation of downstream genes of Meox2, decrease in cell growth and loss of 
cellular adhesion. Once the relationship between Wt1 and Meox2 are fully understood, 
we will have an insight on the functional role(s) of WT1 and MEOX2 during Wilms 
tumorigenesis and have the advantage of being able to develop better therapeutics for 
WTs.  
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Appendix 
Appendix Table 1. Putative Targets of WT1 
 A, Activate and R, Repress 
Gene ID Protein Location Regulation Reference 
ABCB1 ATP-bndg cassette sub-fam B mbr 1 (MDR-1) 7q21.12 R McCoy, 1999 
AMHR2 anti-Mullerian hormone receptor 2 12q13.13 A Klattig, 2007 
AR androgen receptor Xq12 R Shimamura, 1997 
AREG amphiregulin 4q13.3 A Lee, 1999 
BAG3 BCL2-associated athanogene 3 10q26.11 A Cesaro, 2010 
BAK1 BCL2 antagonist/killer 1 6p21.31 A Morrison, 2005 
BCL2 B-cell lymphoma prot 2 beta isoform 18q21.33 A Mayo, 1999 
BCL2A1 BCL2-related protein A1 15q25.1 A Simpson, 2006 
CCNE1 cyclin E1 19q12 R Loeb, 2002 
CCNG1 cyclin G1 5q34 A Wagner, 2001 
CDH1 cadherin 1, type 1; E-cadherin 16q22.1 A Hosono, 2000 
CDH5 cadherin 5, vascular endothelial cadherin 16q21 A Kirschner, 2010 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21) 6p21.31 A Englert, 1997 
COL4A1 alpha 1 type IV collagen 13q34 A Hosono, 1999 
COL4A2 alpha 2 type IV collagen 13q34 A Hosono, 1999 
CSF1 colony stimulating factor 1 1p13.3 R Harrington, 1993 
CTGF connective tissue growth factor 6q23.2 R Stanhope-Baker, 2000 
CXXC5 
(WID) 
CXXC-type zinc finger protein 5 5q31.3 A Kim, 2010 
CX3CL1 chemokine (C-X3-C) ligand1 16q13 A Kim, 2007 
DMTF1 cyclin-dependent myb-like protein 1, WT1-induced inhibitor of DSH 7q21.12 R Tschan, 2008 
EGFR epidermal growth factor receptor 7p11.2 R Englert, 1995 
EGR1 early growth response 1 5q31.2 R Madden, 1991 
EPO erythropoeitin 7q22.1 A Dame, 2006 
EPOR erythropoeitin receptor 19p13.2 A Kirschner, 2008 
EREG epiregulin 4q13.3 A Kim, 2007 
ESR estrogen receptor 6q25.1 R Han, 2008 
GNAI2 G-protein alpha i-2 3p21.31 R Kinane, 1996 
HBEGF heparin-binding EGF-like growth factor 5q31.3 A Kim, 2007 
HOXA10 homeobox gene 7p15.2 R Andikyan, 2009 
HSPA4 heat shock 70kDa protein 4 isoform a 5q31.1 A Maheswaran, 1998 
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HSPG2 heparan sulfate proteoglycan 2 (perlecan) 1p36.12 A Hosono, 1999 
IFI16 interferon-inducible protein 16 1q23.1 A Kim, 2008 
IGF1R insulin-like growth factor 1 receptor 15q26.3 R Werner, 1993 
IGF2 insulin-like growth factor 2 11p15.5 R Drummond, 1992 
IGFBP4 insulin-like growth factor binding prot 4 17q21.2 R Wagner, 2001 
     
IL10 interleukin-10 1q32.1 A Sciesielski, 2010 
INHA inhibin alpha 2q35 R Hsu, 1995 
IRF8 interferon regulatory factor 8 16q24.1 R Vidovic, 2010 
ITGA4 integrin alpha 4 2q31.3 A Kirschner, 2006 
ITGA8 integrin alpha 8 10p13 R Hosono, 1999 
JUNB Proto-oncogene JunB 19p13.13 A Kim, 2007 
MDK midkine (neurite growth-promoting factor 2) 11p11.2 R Adachi, 1996 
MIS Mullerian inhibiting substance 19p13.3 A Nachtigal, 1998 
MKP3 mitogen-activ prot kinase phosph 3 (DUSP6) 12q21.33 A Morrison, 2008 
MMP9 matrix metalloproteinase-9 20q13.12 R Marcet-Palacios, 2007 
MYB c-myb myeloblastosis viral onc hom 6q23.3 R McCann, 1995 
MYC c-myc oncogene 8q24.21 A Han, 2004 
MYCN n-myc myelocytomatosis viral related onc 2p24.3 R Zhang, 1999 
NDRG2 N-myc downstream regulated gene 2 14q11.2 A Svensson, 2007 
NES nestin 1q23.1 A Wagner, 2006 
NOV novH, nephroblastoma overexpressed gene 8q24.12 R Martinerie, 1996 
NPHS1 nephrin 19q13.12 A Wagner, 2004 
NR0B1 nucl recep subfamily 0, grp B, mbr 1 (Dax-1) Xp21.2 A Kim, 1999 
NR5A1/SF1 nuclear receptor subfamily 5, group A (SF-1) 9q33.3 A Wilhelm, 2002 
NTRK2 neurotrophin receptor TrkB 9q21.33 A Wagner, 2005 
ODC ornithine decarboxylase 1 2p25.1 R Moshier, 1996 
PAX2 paired box protein 2 10q24.31 R Ryan, 1995 
PDGFA platelet-derived growth factor alpha 7p22 R Wang, 1992 
PODXL podocalyxin-like (podocalyxin) 7q32.3 A Palmer, 2001 
POU4F2 POU domain, class 4, transc factor 2 4q31.22 A Wagner, 2003 
RARA retinoic acid receptor, alpha 17q21.2 R Goodyer, 1995 
RBBP7 Rb binding protein 7 (RbAp46) Xp22.2 A Guan, 1998 
SALL2 Sal-like 2 (HSAL2) 14q11.2 R Ma, 2001 
SCRIB Scribble 8q24.3 A Wells, 2010 
SDC1 syndecan 1 2p24.1 A Cook, 1996 
SLC6A6 solute carrier fam 6 (neurotrans transp, taurine, TauT) 3p25.1 A Han, 2003 
SNAI1 Snail 20q13.13 A Martinez-Estrada, 2010 
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SNAI2 Slug 8q11.21 A Kim, 2007 
SOD1 superoxide dismutase 1 21q22.11 A Minc, 1999 
SOX9 transcription factor SOX9 17q24.3 A Gao, 2006 
SPRY1 Sprouty homolog 1 4q28.1 A Gross, 2003 
SREBP2 sterol reg element binding transc factor 17p11.2 A Rae, 2004 
SRY sex determining region Y Yp11.31 A Matsuzawa-Watanabe, 2003 
STAT3 signal transducer and activator of transcription 3 17q21.2 A Inoue, 1998 
STIM1 stromal interaction molecule1 11p15.5 R Ritchie, 2010 
TBXA2R thromboxane A2 receptor 19p13.3 R Gannon, 2008 
TERT telomerase reverse transcriptase 5p15.33 R Oh, 1999 
TGFB transforming growth factor, beta 1 19q13.2 R Dey, 1994 
THBS1 thrombospondin 1 15q14 R Dejong, 1999 
VDR vit D (1,25- dihydroxyvitamin D3) receptor 12q13.11 A Wagner, 2001 
VEGF vascular endothelial growth factor 6p21.1 A Hanson, 2007 
WNT4 wingless-type MMTV integ site fam, member 4 1p36.12 A Sim, 2002 
WT1 Wilms tumor 1 11p13 R Rupprecht, 1994 
   A, Activate and R, Repress 
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Appendix Table 2. Calculating the Relative Gene Expression of Validated Genes 
(n=12) 
CXXC4: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
7.009 7.009 10.856 10.856 -3.223 0.107 
6.850 6.850 10.914 10.914  -9.337 
7.176 7.176 9.937 9.937   
7.241 7.241 11.008 11.008   
10.029 10.029 12.556 12.556   
9.908 9.908 12.653 12.653   
6.287 6.287 8.368 8.368   
6.102 6.102 8.498 8.498   
6.511 6.511 12.169 12.169   
6.616 6.616 15.053 15.053   
8.126 8.126 8.111 8.111   
7.987 7.987 8.396 8.396   
7.487 1.309 10.710 2.162   
 
DDR1: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
5.978 5.978 5.242 5.242 -0.661 0.633 
6.041 6.041 5.241 5.241  -1.581 
6.047 6.047 7.374 7.374   
5.976 5.976 7.400 7.400   
5.898 5.898 4.349 4.349   
6.040 6.040 4.279 4.279   
6.771 6.771 5.243 5.243   
6.807 6.807 5.217 5.217   
4.870 4.870 4.008 4.008   
5.000 5.000 4.040 4.040   
5.382 5.382 4.781 4.781   
5.337 5.337 5.046 5.046   
5.846 0.609 5.185 1.132   
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FST: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
9.966 9.966 6.678 6.678 3.694 12.938 
10.074 10.074 6.810 6.810   
12.819 12.819 8.787 8.787   
12.951 12.951 7.781 7.781   
12.666 12.666 7.597 7.597   
13.033 13.033 8.333 8.333   
10.870 10.870 8.305 8.305   
15.658 15.658 9.423 9.423   
14.482 14.482 9.360 9.360   
9.735 9.735 9.119 9.119   
9.804 9.804 9.236 9.236   
12.005 2.042 8.312 0.989   
 
HIPK2: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
3.610 3.610 4.184 4.184 -1.176 0.443 
3.629 3.629 4.285 4.285  -2.260 
1.780 1.780 4.038 4.038   
1.749 1.749 4.253 4.253   
4.315 4.315 3.109 3.109   
4.473 4.473 3.207 3.207   
2.546 2.546 5.863 5.863   
2.514 2.514 5.953 5.953   
1.880 1.880 2.244 2.244   
1.938 1.938 2.341 2.341   
2.843 1.070 4.341 4.341   
  4.413 4.413   
  4.019 1.168   
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MEOX2: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
13.369 13.369 5.934 5.934 5.360 41.069 
13.473 13.473 6.361 6.361   
12.099 12.099 4.404 4.404   
12.305 12.305 5.087 5.087   
11.029 11.029 5.227 5.227   
10.810 10.810 5.996 5.996   
9.914 9.914 4.608 4.608   
9.179 9.179 5.214 5.214   
13.068 13.068 6.477 6.477   
13.152 13.152 6.621 6.621   
7.082 7.082 6.370 6.370   
7.104 7.104 5.962 5.962   
11.049 2.308 5.689 0.754   
 
MLLT3: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
8.550 8.550 7.819 7.819 3.335 10.091 
8.570 8.570 8.714 8.714   
14.635 14.635 7.666 7.666   
15.724 15.724 8.366 8.366   
7.384 7.384 7.832 7.832   
7.705 7.705 7.737 7.737   
12.549 12.549 8.303 8.303   
14.656 14.656 8.488 8.488   
15.321 15.321 10.149 10.149   
12.439 12.439 10.531 10.531   
13.323 13.323 8.562 8.562   
11.896 3.232 8.567 8.567   
  8.561 0.909   
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PRRX1: 
Average STDEV Average STDEV WT-MT Relative Gene Expression 
11.536 11.536 12.771 12.771 3.818 14.099 
11.396 11.396 13.306 13.306   
11.826 11.826 6.368 6.368   
15.108 15.108 6.314 6.314   
15.303 15.303 7.699 7.699   
20.143 20.143 8.038 8.038   
11.795 11.795 7.693 7.693   
12.610 12.610 8.246 8.246   
12.896 12.896 9.331 9.331   
9.411 9.411 10.200 10.200   
9.648 9.648 9.129 9.129   
12.879 3.040 9.643 9.643   
  9.062 2.210   
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Appendix Figure 1. IF Images of the Subcloned Kidney MMCs 
Clone #1: 
  
 
 
 
 
 
 
 
 
 
Clone #2: 
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Clone #3:  
 
 
 
 
 
 
 
 
 
 
Clone #4: 
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Clone #5: 
 
 
 
 
 
 
 
 
 
 
 
Clone #7: 
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Clone #8: 
 
 
 
 
 
 
 
 
 
 
 
Clone #11: 
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Clone #12:  
 
 
 
 
 
 
 
 
 
 
Clone #15: 
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Appendix Figure 2: IF images of the MMCs with the CreERTM Transgene 
F11249 E3 Wt1-/fl; Immorto; CreERTM 
 
 
 
F11254 E2 Wt1-/fl; Immorto; CreERTM 
 
 
87 
 
Appendix Table 3. Calculating the relative gene expression of the Wt1, Tgf-β1, 
Smad3, Meox2, p21 and Itgb5after adenoviral infection  
Wt1 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
8.474 8.474 4.705 4.705 -3.224 0.107 
7.634 7.634 4.291 4.291   
6.790 6.790 4.231 4.231   
7.633 0.842 4.409 0.258   
      
72 Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
7.059 7.059 5.519 5.519 -3.390 0.095 
7.250 7.250 4.647 4.647   
10.483 10.483 4.458 4.458   
8.264 1.924 4.874 0.566   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
4.475 4.475 4.280 4.280 -2.474 0.180 
6.599 6.599 3.757 3.757   
8.293 8.293 3.908 3.908   
6.456 1.913 3.982 0.269   
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Tgf-β1 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
7.185 7.185 8.021 8.021 0.942 1.921 
6.078 6.078 6.605 6.605   
5.966 5.966 7.428 7.428   
6.410 0.674 7.351 0.711   
      
72 Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
6.123 6.123 6.646 6.646 -0.666 0.630 
5.858 5.858 4.120 4.120  -1.587 
6.600 6.600 5.818 5.818   
6.194 0.376 5.528 1.288   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
6.488 6.488 5.875 5.875 -0.616 0.652 
6.186 6.186 5.920 5.920  -1.533 
6.421 6.421 5.450 5.450   
6.365 0.159 5.749 0.259   
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Smad3 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
8.144 8.144 7.037 7.037 -1.584 0.334 
9.148 9.148 7.086 7.086  -2.998 
      
8.646 0.710 7.062 0.034   
      
72 Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
9.384 9.384 8.236 8.236 -0.541 0.687 
8.685 8.685 8.808 8.808  -1.455 
8.844 8.844 8.246 8.246   
8.971 0.366 8.430 0.328   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
9.549 9.549 7.396 7.396 -1.227 0.427 
9.143 9.143 7.643 7.643  -2.341 
8.425 8.425 8.397 8.397   
9.039 0.570 7.812 0.522   
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Meox2 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
11.250 11.250 11.392 11.392 0.494 1.409 
11.435 11.435 12.061 12.061   
11.014 11.014 11.730 11.730   
11.233 0.211 11.728 0.335   
      
72 Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
8.186 8.186 6.156 6.156 -1.028 0.490 
7.137 7.137 7.120 7.120  -2.039 
7.370 7.370 6.333 6.333   
7.564 0.551 6.536 0.513   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
7.070 7.070 12.489 12.489 5.936 61.204 
7.338 7.338 13.589 13.589   
6.953 6.953 13.088 13.088   
7.120 0.197 13.056 0.551   
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p21 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
5.319 5.319 5.705 5.705 0.366 1.289 
5.192 5.192 5.478 5.478   
4.984 4.984 5.410 5.410   
5.165 0.169 5.531 0.155   
      
72  Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
4.848 4.848 5.507 5.507 0.367 1.290 
4.824 4.824 5.331 5.331   
5.056 5.056 4.992 4.992   
4.909 0.127 5.277 0.262   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
4.945 4.945 6.272 6.272 1.294 2.452 
5.278 5.278 6.575 6.575   
5.141 5.141 6.399 6.399   
5.121 0.167 6.415 0.152   
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Itgb5 
48 Cre  48 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
7.532 7.532 8.897 8.897 0.436 1.353 
7.782 7.782 7.623 7.623   
7.861 7.861 7.961 7.961   
7.725 0.172 8.160 0.660   
      
72 Cre  72 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
8.833 8.833 7.327 7.327 -0.911 0.532 
8.909 8.909 8.036 8.036  -1.880 
8.765 8.765 8.411 8.411   
8.836 0.072 7.925 0.551   
      
96 Cre  96 GFP    
Average STDEV Average STDEV Control-Infected Relative Gene Expr 
8.485 8.485 7.234 7.234 -1.100 0.467 
8.559 8.559 7.674 7.674  -2.143 
8.507 8.507 7.345 7.345   
8.517 0.038 7.417 0.229   
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